1. Home
  2. BTOC vs CVKD Comparison

BTOC vs CVKD Comparison

Compare BTOC & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BTOC

Armlogi Holding Corp.

HOLD

Current Price

$0.29

Market Cap

12.9M

Sector

N/A

ML Signal

HOLD

Logo Cadrenal Therapeutics Inc.

CVKD

Cadrenal Therapeutics Inc.

HOLD

Current Price

$5.59

Market Cap

13.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BTOC
CVKD
Founded
2020
2022
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.9M
13.8M
IPO Year
2023
2022

Fundamental Metrics

Financial Performance
Metric
BTOC
CVKD
Price
$0.29
$5.59
Analyst Decision
Hold
Strong Buy
Analyst Count
1
1
Target Price
$2.00
$13.00
AVG Volume (30 Days)
226.6K
43.8K
Earning Date
05-24-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
23.94
EPS
N/A
N/A
Revenue
$190,408,258.00
N/A
Revenue This Year
$34.89
N/A
Revenue Next Year
$14.53
N/A
P/E Ratio
N/A
N/A
Revenue Growth
14.03
N/A
52 Week Low
$0.23
$4.21
52 Week High
$1.78
$17.00

Technical Indicators

Market Signals
Indicator
BTOC
CVKD
Relative Strength Index (RSI) 48.53 50.88
Support Level $0.27 $5.13
Resistance Level $0.34 $6.09
Average True Range (ATR) 0.02 0.54
MACD 0.00 0.14
Stochastic Oscillator 48.76 67.72

Price Performance

Historical Comparison
BTOC
CVKD

About BTOC Armlogi Holding Corp.

Armlogi Holding Corp is a fast-growing U.S.-based warehousing and logistics service provider that offers a comprehensive package of supply-chain solutions relating to warehouse management and order fulfillment. The company provides one-stop warehousing and logistics services to cross-border e-commerce merchants outside the U.S. who seek to sell in the U.S. market. The warehouses are equipped with automated sorting systems, heavy-duty forklifts, and pallets and trays that are suitable for processing bulky items. The services of the company include customs brokerage services, transportation of merchandise to U.S. warehouses, and warehouse management and order fulfillment services.

About CVKD Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.

Share on Social Networks: